Wolke Robin, Becktepe Jos Steffen, Paschen Steffen, Helmers Ann-Kristin, Kübler-Weller Dorothee, Youn Jinyoung, Brinker Dana, Bergman Hagai, Kühn Andrea A, Fasano Alfonso, Deuschl Günther
Department of Neurology UKSH, Christian-Albrechts University Kiel Kiel Germany.
Department of Neurosurgery UKSH, Christian-Albrechts University Kiel Kiel Germany.
Mov Disord Clin Pract. 2023 Jul 11;10(8):1181-1191. doi: 10.1002/mdc3.13825. eCollection 2023 Aug.
Deep brain stimulation of the subthalamic nucleus (STN-DBS) is an effective and evidence-based treatment for idiopathic Parkinson's disease (iPD). A minority of patients does not sufficiently benefit from STN-DBS.
The predictive validity of the levodopa challenge for individual patients is analyzed.
Data from patients assessed with a preoperative Levodopa-test and a follow-up examination (mean ± standard deviation: 9.15 months ±3.39) from Kiel (n = 253), Berlin (n = 78) and Toronto (n = 98) were studied. Insufficient DBS outcome was defined as an overall UPDRS-III reduction <33% compared to UPDRS-III in med-off at baseline or alternatively if the minimal clinically important improvement of 5 points was not reached. Single UPDRS-items and sub-scores were dichotomized. Following exploratory analysis, we trained supervised regression- and classification models for outcome prediction.
Data analysis confirmed significant correlation between the absolute UPDRS-III reduction during Levodopa challenge and after stimulation. But individual improvement was inaccurately predicted with a large range of up to 30 UPDRS III points. Further analysis identified preoperative UPDRS-III/med-off-scores and preoperative Levodopa-improvement as most influential factors. The models for UPDRS-III and sub-scores improvement achieved comparably low accuracy.
With large prediction intervals, the Levodopa challenge use for patient counseling is limited, though remains important for excluding non-responders to Levodopa. Despite these deficiencies, the current practice of patient selection is highly successful and builds not only on the Levodopa challenge. However, more specific motor tasks and further paraclinical tools for prediction need to be developed.
丘脑底核深部脑刺激术(STN-DBS)是治疗特发性帕金森病(iPD)的一种有效且有循证依据的疗法。少数患者未能从STN-DBS中充分获益。
分析左旋多巴激发试验对个体患者的预测效度。
研究了来自基尔(n = 253)、柏林(n = 78)和多伦多(n = 98)的患者数据,这些患者均接受了术前左旋多巴试验及随访检查(均值±标准差:9.15个月±3.39)。DBS疗效不佳定义为与基线时未服用药物状态下的UPDRS-III相比,UPDRS-III总体降低<33%,或者未达到最小临床重要改善5分。将单个UPDRS项目和子评分进行二分法划分。经过探索性分析后,我们训练了用于结果预测的监督回归和分类模型。
数据分析证实了左旋多巴激发试验期间及刺激后UPDRS-III的绝对降低之间存在显著相关性。但个体改善情况预测不准确,相差幅度高达30个UPDRS III分。进一步分析确定术前UPDRS-III/未服药评分和术前左旋多巴改善情况为最具影响的因素。UPDRS-III及其子评分改善的模型准确性相对较低。
尽管左旋多巴激发试验在患者咨询方面的预测区间较大,但其用途有限,不过对于排除左旋多巴无反应者仍很重要。尽管存在这些不足,但目前的患者选择做法非常成功,且不仅基于左旋多巴激发试验。然而,需要开发更具特异性的运动任务及更多用于预测的辅助临床检查工具。